SCHEMBL27106960

SCHEMBL27106960

COC(=O)[C@H](CO)NC(=O)c1csc(-c2ccc(OC)cc2)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 1/20 0.56
CDC25A P30304 1/20 0.52
CDC25B P30305 1/20 0.52
IRAK4 Q9NWZ3 2/20 0.51
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 2/20 0.49
HPGDS O60760 1/20 0.49
HPGD P15428 1/20 0.49
CHEK1 O14757 1/20 0.47
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
POLB P06746 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GAA P10253 2/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
P2RY12 Q9H244 1/20 0.45
LMNA P02545 1/20 0.45
ALOX12 P18054 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27106959 1.00 TLR7 (0.56) TLR7CDC25ACDC25BIRAK4ALDH1A1
SCHEMBL27141573 0.91 TLR7 (0.56) TLR7CDC25ACDC25BIRAK4ALDH1A1
SCHEMBL27141574 0.91 TLR7 (0.56) TLR7CDC25ACDC25BIRAK4ALDH1A1
SCHEMBL27106466 0.89 TLR7 (0.55) TLR7HPGDSHPGDRAB9ANPC1
SCHEMBL27153238 0.86 TLR7 (0.44) TLR7CDC25ACDC25BIRAK4ALDH1A1
SCHEMBL27153239 0.86 TLR7 (0.44) TLR7CDC25ACDC25BIRAK4ALDH1A1
SCHEMBL27106972 0.84 TLR7 (0.56) TLR7CDC25ACDC25BIRAK4ALDH1A1
SCHEMBL26012509 0.81 SREBF2 (0.47) IRAK4HPGDSRAB9ANPC1POLB
SCHEMBL30807227 0.81 HDAC1 (0.42) KDM4EHPGDSPOLBHDAC1HDAC6
SCHEMBL30807254 0.81 PIN1 (0.48) TLR7CDC25ACDC25BHPGDSRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062407-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER UNIV WAKE FOREST HEALTH SCIENCES (US) 2026-03-05 US disclosed
US-20250381278-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER UNIV WAKE FOREST HEALTH SCIENCES (US) 2025-12-18 US disclosed
EP-4577211-A2 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER Wake Forest University Health Sciences (US) 2025-07-02 EP disclosed
US-20250011316-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER WAKE FOREST UNIVERSITY HEALTH SCIENCES 2025-01-09 US disclosed
WO-2024044744-A2 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2024-02-29 WO disclosed
WO-2024044744-A2 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2024-02-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062407-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER PRDX1, PRDX3, PRDX2 TLR7 3177/4885CDC25A 1670/4885CDC25B 1411/4885
US-20250011316-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER PRDX1, PRDX2, PRDX6 TLR7 3115/4885CDC25A 1349/4885CDC25B 1396/4885
US-20250381278-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER PRDX1, PRDX2, PRDX6 TLR7 3030/4885CDC25A 1280/4885CDC25B 1427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.